PET Detection of CCR2 in Human Atherosclerosis
Washington University School of Medicine
100 participants
Oct 1, 2020
INTERVENTIONAL
Conditions
Summary
: Use of novel radio-pharmaceutical 64CUDOTA-ECL1i to evaluate arterial atherosclrosis
Eligibility
Inclusion Criteria1
- \-
Exclusion Criteria1
- \-
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Patients in Group 1, normal volunteers and patients with carotid and femoral artery disease who will be having surgery, will have a 1 day imaging session lasting approximately 60 minutes with an injection of 64CU-DOTA-ECL1i to visualize the carotid and femoral arteries. Patients with carotid and femoral artery disease will have their plaque specimens collected for further sutdy
Patients in Group 2, who are patients with carotid and femoral artery disease who will not be having surgery will have two imaging sessions 7-14 days apart
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT04537403